… to one TNFi, RTX appears cost-effective with the threshold of 35,000 €/QALY. With the higher
thresholds also other TNFis and ABT might be cost effective. These findings are consistent …

BACKGROUND: Treat to target (TTT) is a broad concept for treating patients with rheumatoid
arthritis (RA). It involves setting a treatment target, usually remission or low disease activity (…

… Best cost-effectiveness and worker productivity with initial triple-DMARD therapy compared
… in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology (Oxford). …

… ) ratio as well as cost-effectiveness investigations are addressed. … PubMed literature search
using ‘rheumatoid arthritis’ as one term … Cost effectiveness was also used as a search term in …

… Given the wide variability in efficacy and costs among these different treatment options,
we sought to determine their cost-effectiveness (CE) in order to guide policy in different cost-…

… cost-effective in the Medicare population compared with either etanercept or adalimumab.
Anakinra is substantially less costly but is also less effective … disease rheumatoid arthritis (RA). …

… This report reviews the clinical effectiveness and cost-effectiveness of adalimumab,
etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha) …

… Patient mortality depends on rheumatoid arthritis life-tables … accepted that etanercept is
cost-effective and recommended its … of other cost-effectiveness questions in rheumatoid arthritis. …

… therapy increases treatment costs; in particular, biologics cost up to … costs associated with
various therapeutic strategies. Health policy analyses use the incremental cost effectiveness …

… effect was maintained [16]. The objective of the present analysis was to estimate the cost‐effectiveness …
The key issue when performing cost‐effectiveness analyses of new treatments in …